Mp12-08 outcomes of Nephrectomy for Renal Cell Carcinoma With Venous Thrombus Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study

Abstract

location. Hilar and retrocaval suspicious lymphadenopathies are associated with higher concordance and increased risk of LNI. In consequence, performing a more extended LND for staging purposes in these patients may allow for a better risk classification and for a better planning of adjuvant treatments.

Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma

“…Reimers et al also cautioned the increased need for time and skill due to the operative challenge and substantial fibrosis in most of the cases. Subsequent larger case series confirmed the feasibility and safety of post-ICI nephrectomy in both open and minimally invasive settings. Gross et al recently reported a large series of 232 patients undergoing CN in the ICI era, 30 of whom received deferred CN; 90% were favorable or intermediate risk and 70% received ICI as a third line or greater treatment, yet no data on perioperative findings or AEs in this subgroup were reported.…”

“…In addition, retrospective studies on deferred CN after ICI showed that the decision of CN was mainly made at the surgeon’s discretion. Nevertheless, patients with favorable or intermediate risk who responded well to the up-front ICI were more likely to undergo CN …”

“…The postoperative complication rate in this study was similar to that of other post-ICI series (Table 3). The same group reported updated data to the American Urological Association in 2022, focusing on the outcomes of nephrectomy and thrombectomy after ICI therapy. In this study of 33 patients with RCC and venous thrombus, the authors showed the feasibility of nephrectomy and thrombectomy after ICI therapy.…”